JP2024012470A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024012470A5 JP2024012470A5 JP2023187803A JP2023187803A JP2024012470A5 JP 2024012470 A5 JP2024012470 A5 JP 2024012470A5 JP 2023187803 A JP2023187803 A JP 2023187803A JP 2023187803 A JP2023187803 A JP 2023187803A JP 2024012470 A5 JP2024012470 A5 JP 2024012470A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- adam10
- peptide
- positions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 claims 151
- 108090000765 processed proteins & peptides Proteins 0.000 claims 125
- 235000001014 amino acid Nutrition 0.000 claims 120
- 108091007504 ADAM10 Proteins 0.000 claims 100
- 102100039673 Disintegrin and metalloproteinase domain-containing protein 10 Human genes 0.000 claims 100
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 42
- 235000018417 cysteine Nutrition 0.000 claims 33
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 33
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Chemical group OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 32
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 30
- 229940024606 amino acid Drugs 0.000 claims 30
- 229920001184 polypeptide Polymers 0.000 claims 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims 29
- 238000006467 substitution reaction Methods 0.000 claims 24
- 235000004279 alanine Nutrition 0.000 claims 22
- 239000004471 Glycine Chemical group 0.000 claims 21
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 21
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Chemical group CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 21
- 239000004473 Threonine Chemical group 0.000 claims 21
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 15
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 claims 11
- 108091007169 meprins Proteins 0.000 claims 11
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical group OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 10
- 102000004961 Furin Human genes 0.000 claims 10
- 108090001126 Furin Proteins 0.000 claims 10
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 10
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical group OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 10
- 235000009582 asparagine Nutrition 0.000 claims 10
- 229960001230 asparagine Drugs 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 235000013922 glutamic acid Nutrition 0.000 claims 10
- 239000004220 glutamic acid Substances 0.000 claims 10
- 238000000034 method Methods 0.000 claims 9
- 230000004048 modification Effects 0.000 claims 8
- 238000012986 modification Methods 0.000 claims 8
- 230000001105 regulatory effect Effects 0.000 claims 8
- 239000004475 Arginine Substances 0.000 claims 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical group OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 7
- 239000004472 Lysine Substances 0.000 claims 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 7
- 235000009697 arginine Nutrition 0.000 claims 7
- 235000003704 aspartic acid Nutrition 0.000 claims 7
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 7
- 230000004071 biological effect Effects 0.000 claims 7
- 235000018977 lysine Nutrition 0.000 claims 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 5
- 238000003776 cleavage reaction Methods 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 230000007017 scission Effects 0.000 claims 5
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 3
- 150000001295 alanines Chemical group 0.000 claims 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000006850 spacer group Chemical group 0.000 claims 3
- 239000000758 substrate Substances 0.000 claims 3
- -1 IL6-R Proteins 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000000415 inactivating effect Effects 0.000 claims 2
- 229960000310 isoleucine Drugs 0.000 claims 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 2
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 2
- 230000006320 pegylation Effects 0.000 claims 2
- 108010032595 Antibody Binding Sites Proteins 0.000 claims 1
- 101800001382 Betacellulin Proteins 0.000 claims 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims 1
- 101710098272 C-X-C motif chemokine 11 Proteins 0.000 claims 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims 1
- 108010078239 Chemokine CX3CL1 Proteins 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 102100020997 Fractalkine Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 102000018710 Heparin-binding EGF-like Growth Factor Human genes 0.000 claims 1
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 claims 1
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 claims 1
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 claims 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 1
- 101000978766 Homo sapiens Neurogenic locus notch homolog protein 1 Proteins 0.000 claims 1
- 101000577202 Homo sapiens Neurogenic locus notch homolog protein 3 Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 1
- 108700003486 Jagged-1 Proteins 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 claims 1
- 102100025247 Neurogenic locus notch homolog protein 3 Human genes 0.000 claims 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 1
- 102100029837 Probetacellulin Human genes 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 102100032702 Protein jagged-1 Human genes 0.000 claims 1
- 108700037966 Protein jagged-1 Proteins 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 125000003147 glycosyl group Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 239000010445 mica Substances 0.000 claims 1
- 229910052618 mica group Inorganic materials 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000003285 pharmacodynamic effect Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000006337 proteolytic cleavage Effects 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000009877 rendering Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000011191 terminal modification Methods 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762566580P | 2017-10-02 | 2017-10-02 | |
| US62/566,580 | 2017-10-02 | ||
| US201762589842P | 2017-11-22 | 2017-11-22 | |
| US62/589,842 | 2017-11-22 | ||
| PCT/US2018/053938 WO2019070685A1 (en) | 2017-10-02 | 2018-10-02 | METHODS AND COMPOSITIONS FOR INHIBITING BIOLOGICAL ACTIVITIES OF ADAM10 |
| JP2020520057A JP7448219B2 (ja) | 2017-10-02 | 2018-10-02 | Ａｄａｍ１０の生物学的活性を阻害するための方法および組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520057A Division JP7448219B2 (ja) | 2017-10-02 | 2018-10-02 | Ａｄａｍ１０の生物学的活性を阻害するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024012470A JP2024012470A (ja) | 2024-01-30 |
| JP2024012470A5 true JP2024012470A5 (enExample) | 2024-06-04 |
Family
ID=65995419
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520057A Active JP7448219B2 (ja) | 2017-10-02 | 2018-10-02 | Ａｄａｍ１０の生物学的活性を阻害するための方法および組成物 |
| JP2023187803A Pending JP2024012470A (ja) | 2017-10-02 | 2023-11-01 | Ａｄａｍ１０の生物学的活性を阻害するための方法および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520057A Active JP7448219B2 (ja) | 2017-10-02 | 2018-10-02 | Ａｄａｍ１０の生物学的活性を阻害するための方法および組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20190345473A1 (enExample) |
| EP (1) | EP3691671A4 (enExample) |
| JP (2) | JP7448219B2 (enExample) |
| AU (1) | AU2018345601B2 (enExample) |
| CA (1) | CA3077694A1 (enExample) |
| IL (1) | IL273725A (enExample) |
| MX (1) | MX2020004218A (enExample) |
| WO (1) | WO2019070685A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL276359B2 (en) | 2018-01-31 | 2025-01-01 | Verra Therapeutics | Methods and compounds for preventing biological activity of a human9 |
| US20220213169A1 (en) * | 2019-05-09 | 2022-07-07 | Verra Therapeutics, Llc | Methods and compositions for inhibiting adam8 biological activities |
| US20250177333A1 (en) * | 2022-03-08 | 2025-06-05 | Nova Southeastern University | Method for treating rheumatoid arthritis (ra) using an enzyme-and substrate selective exosite inhibitor of a disintegrin and metalloprotease 10 (adam10) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003270625A1 (en) | 2002-09-11 | 2004-04-30 | Justus-Liebig-Universität Giessen | Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing |
| JP4699374B2 (ja) * | 2003-05-15 | 2011-06-08 | トラスティーズ オブ タフツ カレッジ | 安定なペプチド及びポリペプチドアナログ治療剤 |
| JP5328155B2 (ja) | 2005-02-02 | 2013-10-30 | マクロジェニックス ウエスト， インコーポレイテッド | Ａｄａｍ−９モジュレータ |
| US20090297507A1 (en) | 2005-04-07 | 2009-12-03 | Albert Lai | ADAM10 in Cancer Diagnosis, Detection and Treatment |
| US7638301B2 (en) * | 2006-08-28 | 2009-12-29 | Biozyme, Inc. | Prodomain modulators of ADAM 10 |
| US20090285840A1 (en) | 2008-04-29 | 2009-11-19 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Methods for treating pathological neovascularization |
| US20090285640A1 (en) | 2008-05-16 | 2009-11-19 | Hilfiker William K | Method for constructing a mechanically stabilized earthen embankment using semi-extensible steel soil reinforcements |
| WO2012064865A1 (en) * | 2010-11-09 | 2012-05-18 | The University Of Chicago | Role of adam10 and its relevance to disease and therapeutics |
| WO2012088105A2 (en) * | 2010-12-20 | 2012-06-28 | Biozyme Inc. | Methods and compositions for predicting disease status in cancer |
| EP3102940B1 (en) | 2014-02-04 | 2019-06-26 | Monash University | Anti-metalloprotease antibody for diagnosis and treatment of cancers |
-
2018
- 2018-10-02 AU AU2018345601A patent/AU2018345601B2/en active Active
- 2018-10-02 US US16/149,764 patent/US20190345473A1/en not_active Abandoned
- 2018-10-02 MX MX2020004218A patent/MX2020004218A/es unknown
- 2018-10-02 JP JP2020520057A patent/JP7448219B2/ja active Active
- 2018-10-02 EP EP18865159.0A patent/EP3691671A4/en active Pending
- 2018-10-02 WO PCT/US2018/053938 patent/WO2019070685A1/en not_active Ceased
- 2018-10-02 CA CA3077694A patent/CA3077694A1/en active Pending
-
2020
- 2020-03-31 IL IL273725A patent/IL273725A/en unknown
-
2022
- 2022-05-19 US US17/748,163 patent/US12297469B2/en active Active
-
2023
- 2023-11-01 JP JP2023187803A patent/JP2024012470A/ja active Pending
-
2025
- 2025-03-06 US US19/072,106 patent/US20250207119A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024012470A5 (enExample) | ||
| ES2393373T3 (es) | Método para la producción de factor-I de crecimiento similar a la insulina | |
| CN101511390B (zh) | 制备胰岛素样生长因子-1与聚(乙二醇)的偶联物的方法 | |
| RU2009134725A (ru) | Варианты трансглутаминазы с улучшенной специфичностью | |
| CN105451755A (zh) | 铁调素类似物和其用途 | |
| PL219605B1 (pl) | Dimeryczne mimetyki peptydów trombopoetynowych wiążące się z receptorem MP1 i wykazujące aktywność trombopoetyczną | |
| JP2014519852A5 (enExample) | ||
| CA2676797A1 (en) | Novel macromolecule transduction domains and methods for identification and uses thereof | |
| PT99565B (pt) | Processo para a preparacao de factores de crescimento de fibroblastos quimerico s | |
| EA032727B1 (ru) | Мутантный резистентный к протеолизу полипептид fgf21 и его применение | |
| CA2337100A1 (en) | Polypeptides of lymphodendritic cell adhesion molecules (ldcams) and polynucleotides encoding the same | |
| AU2008211884A1 (en) | Novel polypeptide having anti-tumor activity | |
| US5854025A (en) | IGF-II analogues | |
| CN116789801B (zh) | 新型胰岛素衍生物及其用途 | |
| RU2003105897A (ru) | Белки урокортина и их применения | |
| WO2020073825A1 (zh) | 一种改善生物活性蛋白性质的载体蛋白 | |
| US20080200378A1 (en) | KGF polypeptide compositions | |
| DE602005025141D1 (de) | In Zellen eindringende Peptide als Träger für Moleküle | |
| US20110071077A1 (en) | Thrombopoietic Compounds | |
| JP2018504381A (ja) | 細胞透過性ペプチド | |
| JPH10338700A (ja) | 新規ペプチド化合物 | |
| TW202038997A (zh) | 胜肽之血中動態改善方法 | |
| KR102166543B1 (ko) | 켈로이드 억제용 조성물 및 그 억제 방법 | |
| AU2002326742A1 (en) | KGF polypeptide compositions | |
| TW202400625A (zh) | 肽以及包含肽之劑 |